Breast Cancer Drug Combination Improved Survival Outcomes
A study found that adding palbociclib to maintenance therapy may extend progression-free survival in some patients.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Is it acceptable to accept higher side effect risks for potentially longer progression-free cancer survival?
Results from the phase 3 PATINA trial showed that adding palbociclib to standard maintenance treatment significantly extended median progression-free survival for patients with hormone receptor-positive, HER2-positive metastatic breast cancer. This treatment approach may offer a new option for those who have not progressed after initial therapy.
Why it matters
By simultaneously targeting both hormone receptor and HER2 signaling pathways, this dual-approach strategy aims to better control cancer growth in patients who have become resistant to single-pathway treatments. It represents a potential shift in how clinicians manage advanced disease following standard initial therapy.
In the phase 3 PATINA trial involving 518 patients, those receiving palbociclib alongside maintenance therapy achieved a median progression-free survival of 44.3 months compared to 29.1 months in the control group. The hazard ratio for progression-free survival was 0.75.
The players
Cleveland Clinic
A prominent medical research and clinical care center that serves as a key site for investigating complex oncology treatments.
The details
The treatment works by combining palbociclib, a CDK4/6 inhibitor, with maintenance trastuzumab and endocrine therapy. While the combination increased progression-free survival, it also led to higher rates of grade 3 or 4 neutropenia, which occurred in 77.8% of the palbociclib arm compared to 7.7% in the control arm. Diarrhea was also reported more frequently in the treatment group, though discontinuation rates remained similar across both study cohorts.
Timeline
September 22, 2026: The PATINA trial data was published in a report.
Health Landscape
This development follows a pattern set by other research into dual-pathway inhibition for metastatic breast cancer. It marks an effort to move beyond single-pathway standard care by addressing the simultaneous dependency of tumor cells on multiple signaling channels.
If you are managing hormone receptor-positive, HER2-positive breast cancer, it is worth discussing with your oncologist whether combination maintenance therapies are relevant to your treatment plan. Ask your physician about potential side effects like neutropenia and how they might be monitored.
The takeaway
This trial suggests that combination therapy may significantly extend the time patients live without cancer progression. Patients should talk to their doctor about the risks and benefits of adding CDK4/6 inhibitors to their existing endocrine and HER2-directed treatment regimens.
Further reading
For more information on the current standard of care and research developments, visit our section on Cancer.
More information
View full details regarding the study design and patient criteria at the ClinicalTrials.gov record for PATINA trial.
Live Poll
Is it acceptable to accept higher side effect risks for potentially longer progression-free cancer survival?
